Combinatorial Effect of Cold Atmosphere Plasma (CAP) and the Anticancer Drug Cisplatin on Oral Squamous Cell Cancer Therapy

Cold atmospheric plasma (CAP) has been extensively investigated in the local treatment of cancer due to its potential of reactive oxygen species (ROS) generation in biological systems. In this study, we examined the synergistic effect of combination of CAP and cisplatin-mediated chemotherapy of oral...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2020-10, Vol.21 (20), p.7646
Main Authors: Lee, Chang-Min, Jeong, Young-Il, Kook, Min-Suk, Kim, Byung-Hoon
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Apoptosis
Apoptosis - drug effects
Brain cancer
Cancer therapies
Carcinoma, Squamous Cell - metabolism
Cell Line, Tumor
Cell Proliferation - drug effects
Cells, Cultured
Chemotherapy
Cisplatin
Cisplatin - pharmacology
Combinatorial analysis
Cytotoxicity
Drug resistance
Drug Synergism
Humans
Mouth Neoplasms - metabolism
Nanoparticles
Oral cancer
Oral squamous cell carcinoma
Oxidative stress
Plasma
Plasma Gases - pharmacology
Reactive oxygen species
Reactive Oxygen Species - metabolism
Squamous cell carcinoma
Synergistic effect
Viability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cold atmospheric plasma (CAP) has been extensively investigated in the local treatment of cancer due to its potential of reactive oxygen species (ROS) generation in biological systems. In this study, we examined the synergistic effect of combination of CAP and cisplatin-mediated chemotherapy of oral squamous cell carcinoma (OSCC) in vitro. SCC-15 OSCC cells and human gingival fibroblasts (HGF-1) cells were treated with cisplatin, and then, the cells were irradiated with CAP. Following this, viability and apoptosis behavior of the cells were investigated. The viability of SCC-15 cells was inhibited by cisplatin with a dose-dependent manner and CAP treatment time. HGF-1 cells also showed decreased viability by treatment with cisplatin and CAP. Combination of 1 μM cisplatin plus 3 min of CAP treatment or 3 μM cisplatin plus 1 min of CAP treatment showed a synergistic anticancer effect with appropriate cytotoxicity against normal cells. ROS generation and dead cell staining were also increased by the increase in CAP treatment time. Furthermore, tumor-suppressor proteins and apoptosis-related enzymes also increased according to the treatment time of CAP. We showed the synergistic effect of cisplatin and CAP treatment against SCC-15 cells with low cytotoxicity against normal cells.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21207646